Risk factors and mortality in the Carbapenem-resistant Klebsiella pneumoniae infection: case control study

Pathogens and Global Health

Volumn 110, Issue 7-8, 2016, Pages 321-325

  Akgul, Fethiye ^a   Bozkurt, Ilkay ^a   Sunbul, Mustafa ^a   Esen, Saban ^a   Leblebicioglu, Hakan ^a  

^a ONDOKUZ MAYIS UNIVERSITY   (Turkey)

Author keywords

Carbapenem resistant klebsiella pneumoniae; klebsiella pneumonia; Mortality; Risk factors

Indexed keywords

ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL GROWTH; CASE CONTROL STUDY; CENTRAL VENOUS CATHETERIZATION; CONTROLLED STUDY; FEMALE; HUMAN; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; TOTAL PARENTERAL NUTRITION; TRACHEOSTOMY; URINARY CATHETER; VERY ELDERLY; ADOLESCENT; ANTIBIOTIC RESISTANCE; DRUG EFFECTS; KLEBSIELLA INFECTIONS; MICROBIOLOGY; MIDDLE AGED; RISK FACTOR; TURKEY; YOUNG ADULT;

ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CARBAPENEMS; CASE-CONTROL STUDIES; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MIDDLE AGED; RISK FACTORS; TURKEY; YOUNG ADULT;

EID: 85000692676     PISSN: 20477724     EISSN: 20477732     Source Type: Journal    
DOI: 10.1080/20477724.2016.1254976     Document Type: Article

References (34)

1. Tängdén T, Giske CG. Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae:clinical perspectives on detection, treatment and infection control. J Intern Med. 2015;277:501–512.10.1111/joim.2015.277.issue-5
2. Doi Y, Paterson DL. Carbapenemase-producing Enterobacteriaceae. Semin Respir Crit Care Med. 2015;36:74–84.
3. Gülmez D, Woodford N, Palepou MF, et al. Carbapenem-resistant Escherichia coli and Klebsiella pneumoniae isolates from Turkey with OXA-48-like carbapenemases and outer membrane protein loss. Int J Antimicrob Agents. 2008;31:523–526.10.1016/j.ijantimicag.2008.01.017
4. Guh AY, Bulens SN, Mu Y, et al. Epidemiology of carbapenem-resistant Enterobacteriaceae in 7 US communities, 2012–2013. JAMA. 2015;314:1479–1487.10.1001/jama.2015.12480
5. Löfmark S, Sjöström K, Mäkitalo B, et al. Carbapenemase-producing Enterobacteriaceae in Sweden 2007–2013:experiences from seven years of systematic surveillance and mandatory reporting. Drug Resist Updat. 2015;20:29–38.10.1016/j.drup.2015.05.001
6. Viale P, Giannella M, Lewis R, et al. Predictors of mortality in multidrug-resistant Klebsiella pneumoniae bloodstream infections. Expert Rev Anti Infect Ther. 2013;11:1053–1063.10.1586/14787210.2013.836057
7. Carvalhaes CG, Cayô R, Gales AC. Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae in the intensive care unit:a real challenge to physicians, scientific community, and society. Shock. 2013;39(Suppl. 1):32–37.10.1097/SHK.0b013e31828faf1f
8. Yamamoto M, Pop-Vicas AE. Treatment for infections with carbapenem-resistant Enterobacteriaceae:what options do we still have? Crit Care. 2014;18:229.10.1186/cc13949
9. Berezin BE, Towner KJ. Acinetobacter spp as nosocomial pathogens. microbiological, clinical and epidemiological features. Clin Microbiol Rev. 1996;9:148–165.
10. Nordmann P. Carbapenemase-producing Enterobacteriaceae:overview of a major public health challenge. Med Mal Infect. 2014;44:51–56.10.1016/j.medmal.2013.11.007
11. Candevir Ulu A, Kurtaran B, Inal AS, et al. Risk factors of carbapenem-resistant Klebsiella pneumoniae infection:a serious threat in ICUs. Med Sci Monit. 2015;21:219–224.
12. Cardoso T, Ribeiro O, Aragão IC, et al. Additional risk factors for infection by multidrug-resistant pathogens in healthcare-associated infection:a large cohort study. BMC Infect Dis. 2012;12:375.10.1186/1471-2334-12-375
13. Jiao Y, Qin Y, Liu J, et al. Risk factors for carbapenem-resistant Klebsiella pneumoniae infection/colonization and predictors of mortality:a retrospective study. Pathog Glob Health. 2015;109:68–74.10.1179/2047773215Y.0000000004
14. Kofteridis DP, Valachis A, Dimopoulou D, et al. Risk factors for carbapenem-resistant Klebsiella pneumoniae infection/colonization:a case-case-control study. J Infect Chemother. 2014;20:293–297.10.1016/j.jiac.2013.11.007
15. Falagas ME, Rafailidis PI, Kofteridis D, et al. Risk factors of carbapenem-resistant Klebsiella pneumoniae infections:a matched case control study. J Antimicrob Chemother. 2007;60:1124–1130.10.1093/jac/dkm356
16. Gasink LB, Edelstein PH, Lautenbach E, et al. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Infect Control Hosp Epidemiol. 2009;30:1180–1185.10.1086/599171
17. Hussein K, Sprecher H, Mashiach T, Oren I, Kassis I, Finkelstein R. Carbapenem resistance among Klebsiella pneumoniae isolates:risk factors, molecular characteristics, and susceptibility patterns. Infect Control Hosp Epidemiol. 2009;30:666–671.10.1086/599166
18. Patel G, Huprikar S, Factor SH, et al. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol. 2008;29:1099–1106.10.1086/596025
19. Daikos GL, Markogiannakis A. Carbapenemase-producing Klebsiella pneumoniae:(when) might we still consider treating with carbapenems? Clin Microbiol Infect. 2011;17:1135–1141.10.1111/j.1469-0691.2011.03553.x
20. Deshpande LM, Rhomberg PR, Sader HS, et al. Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States medical centers:report from the MYSTIC program (1999–2005). Diagn Microbiol Infect Dis. 2006;56:367–372.10.1016/j.diagmicrobio.2006.07.004
21. Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, et al. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother. 2008;52:1028–1033.10.1128/AAC.01020-07
22. Tumbarello M, Trecarichi EM, De Rosa FG, et al. ISGRI-SITA (Italian Study Group on Resistant Infections of the Società Italiana Terapia Antinfettiva). infections caused by KPC-producing Klebsiella pneumoniae:differences in therapy and mortality in a multicentre study. J Antimicrob Chemother. 2015;70:2133–2143.
23. Hoxha A, Kärki T, Giambi C, et al. Attributable mortality of carbapenem-resistant Klebsiella pneumoniae infections in a prospective matched cohort study in Italy, 2012–2013. J Hosp Infect. doi:10.1016/j.jhin.2015.06.018. [Epub ahead of print] PubMed PMID:26319590.
24. Bremmer DN, Clancy CJ, Press EG, et al. KPC-producing Klebsiella pneumoniae strains that harbor AAC(6′)-Ib exhibit intermediate resistance to amikacin. Antimicrob Agents Chemother. 2014;58:7597–7600.10.1128/AAC.03831-14
25. Falagas ME, Rafailidis PI, Kofteridis D, et al. Risk factors of carbapenem-resistant Klebsiella pneumoniae infections:a matched case control study. J Antimicrob Chemother. 2007;60:1124–1130.10.1093/jac/dkm356
26. Hyle EP, Ferraro MJ, Silver M, Lee H, Hooper DC. Ertapenem-resistant Enterobacteriaceae risk factors for acquisition and outcomes. Infect Control Hosp Epidemiol. 2010;31:1242–1249.10.1086/657138
27. Hussein K, Sprecher H, Mashiach T, et al. Carbapenem resistance among Klebsiella pneumoniae isolates:risk factors, molecular characteristics, and susceptibility patterns. Infect Control Hosp Epidemiol. 2009;30:666–671.10.1086/599166
28. Jeon MH, Choi SH, Kwak YG, Chung JW, Lee SO, Jeong JY, et al. Risk factors for the acquisition of carbapenem-resistant Escherichia coli among hospitalized patients. Diagn Microbiol Infect Dis. 2008;62:402–406.10.1016/j.diagmicrobio.2008.08.014
29. Wu D, Cai J, Liu J. Risk factors for the acquisition of nosocomial infectio with carbapenem-resistant Klebsiella pneumoniae. South Med J. 2011;104:106–110.10.1097/SMJ.0b013e318206063d
30. Dizbay M, Guzel Tunccan O, et al. Emergence of carbapenem-resistant Klebsiella spp. infections in a Turkish University hospital:epidemiology and risk factors. J Infect Dev Ctries. 2014;8:44–49.
31. Kofteridis DP, Valachis A, Dimopoulou D, et al. Risk factors for carbapenem-resistant Klebsiella pneumoniae infection/colonization:a case-case-control study. J Infect Chemother. 2014;20:293–297.10.1016/j.jiac.2013.11.007
32. Hyle EP, Lipworth AD, Zaoutis TE, et al. Risk factors for increasing multidrug resistance among extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species. Clin Infect Dis. 2005;40:1317–1324.10.1086/429239
33. Brusselaers N, Vogelaers D, Blot S. The rising problem of antimicrobial resistance in the intensive care unit. Ann Intensive Care. 2011;1:47.10.1186/2110-5820-1-47
34. Papadimitriou-Olivgeris M, Marangos M, Fligou F, et al. KPC-producing Klebsiella pneumoniae enteric colonization acquired during intensive care unit stay:the significance of risk factors for its development and its impact on mortality. Diagn Microbiol Infect Dis. 2013;77:169–173.10.1016/j.diagmicrobio.2013.06.007